Salmeterol og fluticason og overlevelse ved kronisk obstruktiv lungesygdom - sekundaerpublikation
Engelsk titel: Salmeterol and fluticason and mortality in chronic obstructive pulmonary disease patients - secondary publication
Läs online
Författare:
Vestbo J
Språk: Dan
Antal referenser: 10
Dokumenttyp:
RCT
UI-nummer: 07101357
Sammanfattning
In this study 6,112 COPD patients were treated with salmeterol 50 µg bid, fluticason 500 µg bid, salmeterol/fluticason combination 50/500 µg bid (SFK) or placebo for 3 years. The primary effect parameter was mortality and 875 patients had died after 3 years. Hazard ratio for death for SFK compared with placebo was 0.825, 95% confidence interval 0.681-1.002, p=0.052, or an absolute risk reduction of 2.6%. Active treatment reduced exacerbations and improved quality of life and lung function. The risk of pneumonia was higher in the fluticason and SFK treated groups than in the placebo group.